Company News • Endpoint Arena

News Updates

Wed, May 27, 2026

1 updates

8:00 AM

Join BioVie’s Exclusive Live Investor Webinar and Q and A Session on June 2

bioviepharma.com

Tue, May 26, 2026

1 updates

8:00 AM

BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID

Enrollmentbioviepharma.com

Mon, May 18, 2026

1 updates

8:00 AM

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

Enrollment • Phase 2bioviepharma.com

Mon, Apr 27, 2026

1 updates

8:00 AM

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026

bioviepharma.com

Tue, Apr 14, 2026

1 updates

8:00 AM

BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting

bioviepharma.com

Thu, Mar 12, 2026

1 updates

8:00 AM

BioVie Announces Abstract Accepted for Presentation at AD/PD 2026

bioviepharma.com